Talenom

Company report

04/21/2023 08:05



Juha Kinnunen +358 40 778 1368 juha.kinnunen@inderes.fi



This report is a summary translation of the report "Ryppyjä kannattavuudessa" published on 4/21/2023 at 8:06 am



Wrinkles in profitability

We reiterate our Accumulate recommendation for Talenom and revise our target price to EUR 8.8 (previous EUR 9.0). The Q1 result was a clear disappointment to the company due to weak profitability, which put our earnings estimates under pressure. Although earnings growth currently looks dismal due to heavily declining profitability it is a strategic choice by the company and profitability will eventually turn after the international growth spurt. In the longer term, the current valuation (2024e P/E 28x and EV/EBITDA 11x) is moderate but requires patience to look at the growth story beyond the profitability slump and confidence in international success.

Q1 result clearly below expectations

Talenom's net sales grew as expected by 24.2% in Q1. About 60% of net sales growth came from acquisitions and 40% was organic, which means organic growth was at a good level of almost 10%. On the cost side, however, there was clearly more headwind than we expected and EBITDA was EUR 8.4 million, or 26.7% of net sales, in the seasonally strong period. This was a clear disappointment (estimate 9.5 MEUR) and clearly behind the comparison period (Q1'22: 8.9 MEUR and 35.2%). The main reasons were the loss-making system platform in Spain (-0.5 MEUR) and exceptional costs related to acquisition (-0.5 MEUR), but cost inflation was also significantly faster than we predicted in the Finnish core business. This will be corrected with already made significant price increases, but in Sweden and Spain the road to significant profitability improvements is long. In Sweden, however, implementation of own systems has progressed as planned and the figures are on the rise.

Guidance buffer was eaten in Q1 but big picture largely unchanged

Talenom still estimates that 2023 net sales will be about EUR 120-130 million and that its euro-denominated EBITDA and operating profit will grow from 2022. In terms of net sales and EBITDA, the guidance is easily achievable, but in terms of EBIT, the buffer is significantly lower after the weak Q1. We now estimate that Talenom's 2023 EBIT will be EUR 15.5 million, compared to EUR 15.3 million last year. In Spain, the system platform will cause significant losses also in the coming quarters, but the recovery of Finnish profitability to a "normal" excellent level with price increases and Sweden's relatively stable profitability will be sufficient to achieve our current estimates. Our earnings estimate for the next few years decreased by 5-10%, focusing on the bottom lines, due to a faster than expected increase in financial costs. The big picture remains unchanged: strong acquisition-driven growth continues and, if profitability improvements are successful in Sweden, the road is open for earnings growth after this year's profitability slump. Turnaround is expected already in 2024.

The fruits of international growth are slowly ripening

Talenom's valuation multiples are high with this year's result (2023e P/E 35x and EV/EBIT 31x), but as the direction of earnings growth turns next year, the valuation looks reasonable (2024e P/E 28x and EV/EBIT 23x). The company produces operational cash flow efficiently, and EV/EBITDA that reflects this reasonably is only 12x with 2023 estimates. However, the company allocates the cash flow to international growth, which we believe will create value in the long term, once Talenom gets the "machine working" especially in Sweden. Although this involves many risks, recent acquisitions have mainly been carried out with reasonable valuations (EV/EBITDA 4-6x), making it unlikely that value is destroyed. We find the risk/return ratio sufficient, but the Talenom journey still requires patience.

Recommendation

Accumulate

(previous Accumulate)

EUR 8.80

(previous EUR 9.00)

Share price:

7,88



Key figures

| | 2022 | 2023 e | 2024e | 2025 e |
|------------------|--------|---------------|--------|---------------|
| Revenue | 102 | 127 | 158 | 193 |
| growth-% | 23% | 25% | 24% | 22% |
| EBIT adj. | 15.3 | 15.5 | 19.6 | 25.6 |
| EBIT-% adj. | 15.0 % | 12.1 % | 12.4 % | 13.2 % |
| Net Income | 11.8 | 10.0 | 13.1 | 16.7 |
| EPS (adj.) | 0.27 | 0.22 | 0.29 | 0.36 |
| | | | | |
| P/E (adj.) | 35.4 | 35.8 | 27.6 | 21.9 |
| P/B | 7.5 | 6.2 | 5.8 | 5.2 |
| Dividend yield-% | 1.9 % | 2.4 % | 2.5 % | 2.7 % |
| EV/EBIT (adj.) | 31.1 | 27.8 | 23.0 | 18.1 |
| EV/EBITDA | 14.8 | 11.9 | 10.9 | 9.6 |
| EV/S | 4.6 | 3.4 | 2.9 | 2.4 |

Source: Inderes

Guidance

(Unchanged)


Talenom estimates that 2023 net sales will be about EUR 120-130 million and that its euro-denominated EBITDA and operating profit will grow from 2022.

Share price



Source: Millistream Market Data AB

Revenue and EBIT %



EPS and dividend



Source: Inderes

M

Value drivers

- Strong earnings growth after the acquisitiondriven growth phase
- Clear competitive advantages will continue to contribute to increasing market share
- Strengthening market position in Sweden and profitability improvement
- Fragmented market is transforming, which opens new opportunities
- Business model that utilizes economies of scale strengthens with growth
- Expansion in Spain and elsewhere in Europe



Risk factors

- Failure in improving Sweden's profitability
- Failure in internationalization
- Development of the interest environment and drop of acceptable valuation multiples
- Competitive advantage relies on technology, whose development tends to be fast
- Potential drop in customer retention
- Potential tightening competition in digital financial management
- Transformation can bring new challengers to the industry

| Valuation | 2023 e | 2024e | 2025 e |
|----------------------------|---------------|--------|---------------|
| Share price | 7.88 | 7.88 | 7.88 |
| Number of shares, millions | 45.4 | 45.9 | 46.4 |
| Market cap | 358 | 362 | 366 |
| EV | 431 | 450 | 463 |
| P/E (adj.) | 35.8 | 27.6 | 21.9 |
| P/E | 35.8 | 27.6 | 21.9 |
| P/FCF | neg. | neg. | 98.3 |
| P/B | 6.2 | 5.8 | 5.2 |
| P/S | 2.8 | 2.3 | 1.9 |
| EV/Sales | 3.4 | 2.9 | 2.4 |
| EV/EBITDA | 11.9 | 10.9 | 9.6 |
| EV/EBIT (adj.) | 27.8 | 23.0 | 18.1 |
| Payout ratio (%) | 86.4 % | 70.0 % | 58.4 % |
| Dividend yield-% | 2.4 % | 2.5 % | 2.7 % |
| | | | |

Q1 result clearly below expectations

Turnover in line with our expectations

Talenom's net sales grew by 24.2% in Q1 to EUR 31.3 million which was also our estimate. About 60% of net sales growth came from acquisitions and 40% was organic, which means organic growth was at a good level of almost 10%. We expected a bigger contribution from the numerous acquisitions that the company has recently carried out especially in Sweden and Spain. Finland's net sales were EUR 23.4 million (+11.5%), Sweden's EUR 6.7 million (+69%) and other countries' EUR 1.2 million (+372%). Other countries include Spain and small business in Italy.

Organic growth was driven by the Finnish core business, which benefited slightly from the significant price increases initiated in March (9.4% index increase). However, this will be fully reflected from Q2 onwards, with potential for up to 15% organic growth at that time. In the face of the economic headwind, our estimates are slightly lower, but we believe that the fact that the price increases have been generally accepted and have not led to substantial customer churn is essential. This reflects Talenom's pricing power and the fact that customers are on average very satisfied with the company's services. The

company has been able to sell increasingly broader service packages.

Minor challenges on the profitability side

Talenom's EBITDA in Q1 was EUR 8.4 million, or 26.7% of net sales. This was a clear disappointment (estimate 9.5 MEUR) and clearly behind the comparison period (Q1'22: 8.9 MEUR and 35.2%). EBITDA was depressed by the system platform acquired in Spain in fall 2022 that had a weakening effect of around EUR 0.5 million on EBITDA. This was, however, known after the Nomo acquisition, so it does not work as an actual explanation for the disappointment. By contrast, the weakening effect of non-recurring items related to acquisitions and other expenses was EUR 0.5 million compared to the comparison period. This includes exceptional items such as a reassessment of the additional purchase prices for acquisitions, so the adjusted figure better reflects operational development. However, we have not made any actual adjustments as acquisitions are at the heart of Talenom's strategy.

Q1 EBIT was only EUR 3.5 million while our estimate was EUR 4.3 million. The EBIT margin was therefore only 11.0% in the seasonally strong period compared

to 19.3% in the comparison period. Profitability was naturally depressed by investments in growth, wage inflation, as well as integration and other costs arising from acquisitions. In any case, the cost structure has risen clearly faster than we expected. Net financial expenses also increased heavily and amounted to EUR 0.7 million (Q1'22: 0.2 MEUR) after the interest rate adjustment.

In Finland, profitability was still excellent, but weakened significantly from the comparison period. EBITDA was 35.4%, while in Q1'22 it was still 39.5%. In Finland, however, the situation is practically corrected when the price increases take effect. In Sweden, EBITDA was 11.9% and EBIT 3.2%, and both showed marginal positive development. Sweden's profitability is still burdened by strengthening the organization, accelerating integration, and implementation of the own software. These will keep the organization busy in the future, making organic growth more difficult. The weak Swedish krona also had a negative impact on the development of the euro-denominated EBITDA. In Spain, the business has so far been heavily loss-making, where the already mentioned system platform naturally plays a huge role.

| Estimates MEUR / EUR | Q1'22 Comparison | Q1'23 Actualized | Q1'23e Inderes | Q1'23e Consensus | Conse | ensus High | Difference (%) Act. vs. inderes | 2023e Inderes |
|----------------------|---------------------|---------------------|-------------------|---------------------|-------|---------------|---------------------------------|------------------|
| Revenue | 25.2 | 31.3 | 31.3 | | | | 0% | 127 |
| EBITDA | 8.9 | 8.4 | 9.5 | | | | -12% | 36.2 |
| EBIT | 4.9 | 3.5 | 4.3 | | | | -20% | 15.5 |
| EPS (adj.) | 0.09 | 0.05 | 0.07 | | | | -35% | 0.22 |
| Revenue growth-% | 24.1% | 24.2 % | 24.0 % | | | | 0.2 pp | 24.8 % |
| EBIT-% (adj.) | 19.3 % | 11.0 % | 13.9 % | | | | -2.8 pp | 12.1 % |

Lähde: Inderes

Guidance buffer was eaten up in Q1

Guidance unchanged, but risks increased

As expected Talenom reiterated the guidance that estimates that 2023 net sales will be about EUR 120-130 million and that its euro-denominated EBITDA and operating profit will grow from 2022. In terms of net sales (estimate 127 MEUR) and EBITDA (estimate 36.3 MEUR), the guidance is easily achievable, but in terms of EBIT, the buffer is significantly lower after the weak Q1 and partly exceptional costs.

We now estimate that Talenom's 2023 EBIT will be EUR 15.5 million, compared to EUR 15.3 million last year. We do not expect the company to be able to absorb the exceptional expenses of EUR 0.5 million this year, and the Nomo system platform will cause significant losses in Spain also in the coming quarters. The company estimates that it will get the platform to break-even level this year, but we estimate that the EBITDA of the Other countries segment will be 0% in Q4 (other businesses will be profitable at EBTDA level). Still the recovery of Finnish profitability to a "normal" excellent level with price increases and Sweden's relatively stable profitability will be sufficient to achieve our current estimates.

In any case, the company must remain vigilant during the rest of the year, so that the 2023 EBIT guidance can also be reached. We do, however, consider a profit warning unlikely, because the company can control its performance quite well and understands the importance of a negative surprise in a delicate growth phase.

No major changes in the outlook for the next few years

We made minor adjustments to our estimates for the next few years based on the Q1 report. The efficiency and profitability of Finland's core business is difficult to improve further, but the growth outlook is slightly better than our previous expectation. The key to the estimates for the next few years is Sweden, where profitability should gradually start to improve as own software improves efficiency. In the Q1 earnings call, Talenom estimated that it can reduce the time spent on routine tasks by accountants to one-quarter of what is now spent on them. This, combined with the introduction of organic growth in Talenom's operating model opens the way for significant profitability improvements, which will gradually

materialize with implementations and adoption of working methods. Other countries will improve from their current low level, but the road to significant profitability improvements is long. In the end, we made the biggest changes to financing costs that rose even faster and more than anticipated.

We previously expected a slight decrease in Talenom's relative profitability (EBIT %) next year, but after the weak start to 2023, the bottom is expected to be reached already this year (EBIT margin estimate 12.1%). This negative factor, as such, opens the door to earnings growth returning already next year (estimate 12.4%), which would again give the share a clear upward driver.

Large investments will continue

Talenom's net investments were EUR 12.6 million in Q1, while the company's EBITDA (best guess of operational cash flow) was EUR 8.4 million. Of this, EUR 7.2 million was used on acquisitions and EUR 3.8 million on software. At the same time, the company's interest-bearing net liabilities amounted to EUR 68 million, which means a fair 2x ratio relative to EBITDA. We still find the level reasonable for Talenom.

| Estimate revisions MEUR / EUR | 2023 e Old | 2023e New | Change % | 2024e Old | 2024e New | Change % | 2025 e Old | 2025e New | Change % |
|-------------------------------|----------------------|--------------|-------------|---------------------|--------------|-------------|----------------------|--------------|-------------|
| Revenue | 126 | 127 | 1% | 156 | 158 | 1% | 191 | 193 | 1% |
| EBITDA | 37.2 | 36.2 | -3% | 41.3 | 41.2 | 0% | 49.2 | 48.0 | -2% |
| EBIT (exc. NRIs) | 16.2 | 15.5 | -4% | 19.7 | 19.6 | -1% | 26.8 | 25.6 | -5% |
| EBIT | 16.2 | 15.5 | -4% | 19.7 | 19.6 | -1% | 26.8 | 25.6 | -5% |
| PTP | 14.2 | 12.7 | -11% | 17.2 | 16.4 | -5% | 23.1 | 21.1 | -8% |
| EPS (excl. NRIs) | 0.25 | 0.22 | -12% | 0.30 | 0.29 | -5% | 0.39 | 0.36 | -9% |
| DPS | 0.19 | 0.19 | 0% | 0.20 | 0.20 | 0% | 0.21 | 0.21 | 0% |

The fruits of growth are slowly ripening

Earnings potential increases with the expansion

Although Talenom's earnings development currently looks dismal, the company's earnings potential continues to grow with the expansion. At present, international growth strongly dilutes relative profitability but if Talenom's strategy succeeds, the profitability potential of Sweden and other international activities should be in the same ballpark as in Finland. This naturally requires that the company's competitive advantage (business model, processes and technology) is equally strong outside Finland in the long term. Before this, a significantly bigger scale is naturally also required to highlight the benefits of automation.

Profit potential can be simply assessed by comparing profitability abroad with Finland's core business. Finland's EBIT margin has been around 20% in recent years, which reflects the profitability potential. For example, the Swedish business has so far been lossmaking at EBIT level on an annual basis but if the strategy succeeds, the profitability of existing Swedish business could reach 20% in 2027. During 2024, Talenom's own systems should be fully implemented in all existing offices in Sweden, and this would mark the beginning of a three-year profitability improvement. As a result, the current business of about EUR 25 million in net sales could generate around EUR 5 million EBIT in 2027, compared to the current zero EBIT. This would increase the Group's EBIT by almost a third from the 2023 level. The scenario does not consider the growth in Sweden in the next few years, whose profitability potential would be realized at a later date. At the same time, we stress that the model has not been proven outside Finland, so it is only a scenario of Sweden's potential.

We find the valuation multiples reasonable

Talenom's 2023e P/E ratio is clearly over 30x and EV/EBIT is 28x, but despite continued profitability pressure, 2024e ratios (P/E 28x and EV/EBIT 23x) actually in our opinion have some upside when the earnings growth turns around. Although there is considerable uncertainty concerning the success of the company's international growth strategy, we do not believe that the potential can be overlooked either. Thanks to the excellent cash-flow profile of the Finnish core business we estimate that the cash flow of Talenom's business operations is well above EUR 30 million, compared to which the current EV of around EUR 430 million does not sound unreasonable, even if international growth would not generate scalable growth. Recent acquisitions have mainly been carried out with reasonable valuations (EV/EBITDA 4-6x). making it unlikely that value is destroyed. However, a major performance improvement will in principle, wait until 2025-2026 and one must tolerate considerable uncertainty on the way so Talenom does require patience from its shareholders.

Among the most interesting equity stories in Finland

Talenom's equity story has many attractive elements and opportunities that few listed companies in Helsinki have. The business is mainly recurring and defensive, profitability is partially scalable and competitive advantages are strong in the SME sector selected by the company, as evidenced by the excellent profitability in Finland. The company has a strong position in the transforming accounting services industry, and we estimate Talenom to be one of the future winners, at least in Finland. The abundant cash flow from Finland is now being invested in international growth, which opens realistic prospects for success in the European market as well in the long term.

| Valuation | 2023 e | 2024e | 2025 e |
|----------------------------------|---------------|--------|---------------|
| Share price | 7.88 | 7.88 | 7.88 |
| ${\bf Numberofshares, millions}$ | 45.4 | 45.9 | 46.4 |
| Market cap | 358 | 362 | 366 |
| EV | 431 | 450 | 463 |
| P/E (adj.) | 35.8 | 27.6 | 21.9 |
| P/E | 35.8 | 27.6 | 21.9 |
| P/FCF | neg. | neg. | 98.3 |
| P/B | 6.2 | 5.8 | 5.2 |
| P/S | 2.8 | 2.3 | 1.9 |
| EV/Sales | 3.4 | 2.9 | 2.4 |
| EV/EBITDA | 11.9 | 10.9 | 9.6 |
| EV/EBIT (adj.) | 27.8 | 23.0 | 18.1 |
| Payout ratio (%) | 86.4 % | 70.0 % | 58.4 % |
| Dividend yield-% | 2.4 % | 2.5 % | 2.7 % |



Valuation table

| Valuation | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 e | 2024e | 2025 e | 2026e |
|----------------------------|--------|--------|--------|--------|--------|---------------|--------|---------------|--------|
| Share price | 3.18 | 7.50 | 15.1 | 11.7 | 9.39 | 7.88 | 7.88 | 7.88 | 7.88 |
| Number of shares, millions | 41.2 | 41.7 | 43.2 | 43.8 | 44.5 | 45.4 | 45.9 | 46.4 | 46.4 |
| Market cap | 131 | 313 | 650 | 512 | 420 | 358 | 362 | 366 | 366 |
| EV | 149 | 342 | 679 | 552 | 475 | 431 | 450 | 463 | 459 |
| P/E (adj.) | 20.6 | 41.1 | 67.9 | 47.5 | 35.4 | 35.8 | 27.6 | 21.9 | 17.5 |
| P/E | 20.6 | 41.1 | 67.9 | 47.5 | 35.4 | 35.8 | 27.6 | 21.9 | 17.5 |
| P/FCF | 90.2 | neg. | >100 | neg. | neg. | neg. | neg. | 98.3 | 20.9 |
| P/B | 7.0 | 13.3 | 20.2 | 11.5 | 7.5 | 6.2 | 5.8 | 5.2 | 4.5 |
| P/S | 2.7 | 5.4 | 10.0 | 6.2 | 4.1 | 2.8 | 2.3 | 1.9 | 1.6 |
| EV/Sales | 3.1 | 5.9 | 10.4 | 6.7 | 4.6 | 3.4 | 2.9 | 2.4 | 2.1 |
| EV/EBITDA | 10.9 | 18.1 | 29.2 | 19.9 | 14.8 | 11.9 | 10.9 | 9.6 | 8.5 |
| EV/EBIT (adj.) | 17.5 | 32.8 | 52.7 | 37.4 | 31.1 | 27.8 | 23.0 | 18.1 | 14.8 |
| Payout ratio (%) | 59.4 % | 68.4 % | 67.7 % | 69.0 % | 68.3 % | 86.4% | 70.0 % | 58.4% | 49.0 % |
| Dividend yield-% | 2.9 % | 1.7 % | 1.0 % | 1.5 % | 1.9 % | 2.4% | 2.5 % | 2.7 % | 2.8 % |



Peer group valuation

| Peer group valuation | Market cap | EV | EV/I | EBIT | EV/E | BITDA | EV | //S | P | /E | Dividend | d yield-% |
|----------------------|------------|------|-------|-------|-------|-------------|--------------|------------|-------------|-------------|----------|--------------|
| Company | MEUR | MEUR | 2023e | 2024e | 2023e | 2024e | 2023e | 2024e | 2023e | 2024e | 2023e | 2024e |
| Aallon Group | 41 | 39 | 10.3 | 9.2 | 9.3 | 8.2 | 1.2 | 1.1 | 13.6 | 13.0 | 2.1 | 2.2 |
| Fortnox | 3706 | 3700 | 62.5 | 43.9 | 50.6 | 36.4 | 25.0 | 18.9 | 81.9 | 56.7 | 0.2 | 0.3 |
| Admicom | 214 | 209 | 16.8 | 15.1 | 16.6 | 15.0 | 6.2 | 5.8 | 22.0 | 20.3 | 2.8 | 3.0 |
| ECIT | 216 | 286 | 10.4 | 7.8 | 6.3 | 4.9 | 0.9 | 0.8 | 20.8 | 15.2 | 1.7 | 2.2 |
| Administer | 47 | 59 | 19.6 | 9.8 | 7.4 | 5.3 | 0.7 | 0.7 | 40.9 | 13.1 | 3.1 | 4.6 |
| Xero | 8526 | 8526 | 219 | 72 | 55 | 34 | 10.7 | 9.1 | 498 | 107 | | |
| Enento | 390 | 527 | 13.4 | 11.5 | 8.8 | 8.2 | 3.2 | 3.0 | 16.7 | 13.3 | 6.2 | 6.4 |
| Fondia | 32 | 27 | 10.6 | 8.3 | 8.3 | 6.8 | 1.0 | 0.9 | 16.3 | 13.5 | 3.9 | 4.8 |
| Vincit | 75 | 63 | 7.4 | 5.5 | 6.8 | 5.1 | 0.6 | 0.5 | 11.6 | 9.1 | 3.7 | 4.4 |
| Gofore | 395 | 366 | 13.3 | 11.3 | 12.2 | 10.5 | 1.9 | 1.6 | 18.1 | 16.4 | 2.0 | 2.3 |
| Etteplan | 433 | 496 | 16.2 | 14.3 | 9.6 | 8.7 | 1.4 | 1.2 | 19.9 | 18.1 | 2.5 | 2.8 |
| Talenom (Inderes) | 358 | 431 | 27.8 | 23.0 | 11.9 | 10.9 | 3.4 | 2.9 | 35.8 | 27.6 | 2.4 | 2.5 |
| Average | | | 36.3 | 19.0 | 17.4 | 13.0 | 4.8 | 4.0 | 69.0 | 26.9 | 2.8 | 3.3 |
| Median | | | 13.4 | 11.3 | 9.3 | 8.2 | 1.4 | 1.2 | 19.9 | 15.2 | 2.7 | 2.9 |
| Diff-% to median | | | 109% | 103% | 28% | 33 % | <i>150</i> % | 130% | 80 % | 82 % | -9% | -12 % |

Source: Refinitiv / Inderes

Income statement

| Income statement | 2021 | Q1'22 | Q2'22 | Q3'22 | Q4'22 | 2022 | Q1'23 | Q2'23e | Q3'23e | Q4'23e | 2023 e | 2024e | 2025 e | 2026 e |
|------------------------|--------|--------|--------|---------|---------|--------|---------|--------|--------|--------|---------------|--------|---------------|---------------|
| Revenue | 82.8 | 25.2 | 27.0 | 23.6 | 26.3 | 102 | 31.3 | 34.0 | 29.5 | 32.7 | 127 | 158 | 193 | 222 |
| EBITDA | 27.7 | 8.9 | 9.3 | 7.3 | 6.6 | 32.0 | 8.4 | 10.1 | 8.9 | 8.9 | 36.2 | 41.2 | 48.0 | 53.8 |
| Depreciation | -12.9 | -4.0 | -4.2 | -4.2 | -4.4 | -16.8 | -4.9 | -5.2 | -5.3 | -5.3 | -20.7 | -21.6 | -22.4 | -22.7 |
| EBIT (excl. NRI) | 14.8 | 4.9 | 5.1 | 3.1 | 2.2 | 15.3 | 3.5 | 4.9 | 3.6 | 3.6 | 15.5 | 19.6 | 25.6 | 31.1 |
| EBIT | 14.8 | 4.9 | 5.1 | 3.1 | 2.2 | 15.3 | 3.5 | 4.9 | 3.6 | 3.6 | 15.5 | 19.6 | 25.6 | 31.1 |
| Net financial items | -0.8 | -0.1 | -0.1 | -0.3 | -0.2 | -0.7 | -0.7 | -0.7 | -0.7 | -0.7 | -2.8 | -3.2 | -4.4 | -4.7 |
| PTP | 14.0 | 4.7 | 5.1 | 2.8 | 2.0 | 14.6 | 2.7 | 4.2 | 2.9 | 2.9 | 12.7 | 16.4 | 21.1 | 26.4 |
| Taxes | -3.2 | -1.0 | -1.0 | -0.6 | -0.1 | -2.8 | -0.7 | -0.8 | -0.6 | -0.6 | -2.7 | -3.3 | -4.4 | -5.5 |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net earnings | 10.8 | 3.7 | 4.1 | 2.2 | 1.8 | 11.8 | 2.1 | 3.3 | 2.3 | 2.3 | 10.0 | 13.1 | 16.7 | 20.8 |
| EPS (adj.) | 0.25 | 0.09 | 0.09 | 0.05 | 0.04 | 0.27 | 0.05 | 0.07 | 0.05 | 0.05 | 0.22 | 0.29 | 0.36 | 0.45 |
| EPS (rep.) | 0.25 | 0.09 | 0.09 | 0.05 | 0.04 | 0.27 | 0.05 | 0.07 | 0.05 | 0.05 | 0.22 | 0.29 | 0.36 | 0.45 |
| | | | | | | | | | | | | | | |
| Key figures | 2021 | Q1'22 | Q2'22 | Q3'22 | Q4'22 | 2022 | Q1'23 | Q2'23e | Q3'23e | Q4'23e | 2023 e | 2024e | 2025 e | 2026 e |
| Revenue growth-% | 27.1 % | 24.1 % | 26.2 % | 21.7 % | 21.1 % | 23.3 % | 24.2 % | 26.0 % | 25.0 % | 24.0 % | 24.8 % | 23.6 % | 22.5 % | 15.0 % |
| Adjusted EBIT growth-% | 14.6 % | 10.2 % | 24.0 % | -10.8 % | -20.5 % | 3.4 % | -28.9 % | -5.2 % | 15.9 % | 63.0 % | 1.3 % | 26.6 % | 30.5 % | 21.5 % |
| EBITDA-% | 33.4 % | 35.2 % | 34.4 % | 30.8 % | 25.0 % | 31.4 % | 26.7 % | 29.6 % | 30.1% | 27.2 % | 28.4 % | 26.1 % | 24.9 % | 24.2 % |
| Adjusted EBIT-% | 17.8 % | 19.3 % | 19.0 % | 13.0 % | 8.3 % | 15.0 % | 11.0 % | 14.3 % | 12.1 % | 11.0 % | 12.1 % | 12.4 % | 13.2 % | 14.0 % |
| Net earnings-% | 13.0 % | 14.9 % | 15.0 % | 9.2 % | 7.0 % | 11.6 % | 6.6 % | 9.8 % | 7.8 % | 7.1 % | 7.8 % | 8.3 % | 8.6 % | 9.4 % |

Balance sheet

| Assets | 2021 | 2022 | 2023 e | 2024e | 2025 e |
|--------------------------|------|------|---------------|-------|---------------|
| Non-current assets | 94.3 | 124 | 148 | 173 | 192 |
| Goodwill | 37.3 | 55.0 | 69.0 | 83.0 | 97.0 |
| Intangible assets | 44.7 | 55.9 | 65.6 | 74.8 | 80.1 |
| Tangible assets | 2.8 | 2.8 | 3.0 | 3.8 | 3.3 |
| Associated companies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other investments | 0.9 | 0.3 | 0.3 | 0.3 | 0.3 |
| Other non-current assets | 8.6 | 9.9 | 10.1 | 10.3 | 10.5 |
| Deferred tax assets | 0.1 | 0.4 | 0.4 | 0.4 | 0.4 |
| Current assets | 20.0 | 30.5 | 34.4 | 42.5 | 52.1 |
| Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other current assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Receivables | 9.8 | 14.5 | 16.6 | 20.5 | 25.1 |
| Cash and equivalents | 10.1 | 16.0 | 17.8 | 22.1 | 27.0 |
| Balance sheet total | 118 | 156 | 183 | 213 | 242 |

| Liabilities & equity | 2021 | 2022 | 2023e | 2024e | 2025 e |
|-----------------------------|------|------|-------|-------|---------------|
| Equity | 44.7 | 56.0 | 58.0 | 62.4 | 69.9 |
| Share capital | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Retained earnings | 23.1 | 29.1 | 31.0 | 35.5 | 43.0 |
| Hybrid bonds | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revaluation reserve | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other equity | 21.6 | 26.9 | 26.9 | 26.9 | 26.9 |
| Minorities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Non-current liabilities | 50.4 | 62.3 | 84.9 | 96.5 | 112 |
| Deferred tax liabilities | 2.0 | 3.0 | 3.0 | 3.0 | 3.0 |
| Provisions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Long term debt | 46.2 | 56.4 | 79.0 | 90.6 | 106 |
| Convertibles | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other long term liabilities | 2.2 | 2.8 | 2.8 | 2.8 | 2.8 |
| Current liabilities | 22.6 | 38.0 | 39.8 | 54.3 | 60.9 |
| Short term debt | 3.2 | 13.7 | 11.8 | 19.7 | 18.4 |
| Payables | 16.6 | 24.3 | 28.0 | 34.7 | 42.4 |
| Other current liabilities | 2.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Balance sheet total | 118 | 156 | 183 | 213 | 242 |

DCF calculation

| DCF model | 2022 | 2023 e | 2024 e | 2025e | 2026e | 2027 e | 2028 e | 2029e | 2030e | 2031e | 2032e | TERM |
|---|--------|---------------|---------------|--------|--------|---------------|---------------|--------|--------|--------|--------|--------|
| Revenue growth-% | 23.3 % | 24.8 % | 23.6 % | 22.5 % | 15.0 % | 12.0 % | 8.0 % | 6.0 % | 5.0 % | 5.0 % | 3.0 % | 3.0 % |
| EBIT-% | 15.0 % | 12.1 % | 12.4 % | 13.2 % | 14.0 % | 15.0 % | 15.0 % | 15.0 % | 15.0 % | 14.5 % | 14.5 % | 14.5 % |
| EBIT (operating profit) | 15.3 | 15.5 | 19.6 | 25.6 | 31.1 | 37.3 | 40.3 | 42.7 | 44.8 | 45.5 | 46.8 | |
| + Depreciation | 16.8 | 20.7 | 21.6 | 22.4 | 22.7 | 25.8 | 24.6 | 24.5 | 24.1 | 24.6 | 25.1 | |
| - Paid taxes | -2.1 | -2.7 | -3.3 | -4.4 | -5.5 | -6.9 | -7.7 | -8.3 | -8.9 | -9.1 | -9.4 | |
| - Tax, financial expenses | -0.1 | -0.6 | -0.7 | -1.0 | -1.0 | -1.0 | -0.9 | -0.7 | -0.6 | -0.6 | -0.6 | |
| + Tax, financial income | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| - Change in working capital | 0.2 | 1.6 | 2.7 | 3.2 | 2.6 | 2.4 | 1.8 | 1.4 | 1.3 | 1.3 | 0.8 | |
| Operating cash flow | 30.0 | 34.5 | 40.0 | 45.8 | 49.8 | 57.6 | 58.2 | 59.6 | 60.8 | 61.9 | 62.9 | |
| + Change in other long-term liabilities | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| - Gross CAPEX | -44.5 | -43.1 | -44.1 | -42.1 | -32.3 | -26.9 | -25.9 | -21.0 | -25.2 | -25.6 | -27.7 | |
| Free operating cash flow | -13.8 | -8.5 | -4.1 | 3.7 | 17.5 | 30.7 | 32.3 | 38.6 | 35.6 | 36.3 | 35.3 | |
| +/- Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| FCFF | -13.8 | -8.5 | -4.1 | 3.7 | 17.5 | 30.7 | 32.3 | 38.6 | 35.6 | 36.3 | 35.3 | 732 |
| Discounted FCFF | | -8.1 | -3.6 | 3.0 | 13.2 | 21.4 | 20.9 | 23.1 | 19.7 | 18.6 | 16.8 | 348 |
| Sum of FCFF present value | | 474 | 482 | 485 | 482 | 469 | 448 | 427 | 404 | 384 | 365 | 348 |
| Enterprise value DCF | | 474 | | | | | | | | | | |

2023e-2027e

5%


| Sum of FCFF present value | 4/4 |
|-----------------------------|-------|
| Enterprise value DCF | 474 |
| - Interesting bearing debt | -70.1 |
| + Cash and cash equivalents | 16.0 |
| -Minorities | 0.0 |
| -Dividend/capital return | -8.1 |
| Equity value DCF | 411 |
| Equity value DCF per share | 9.1 |

WACC

| Tax-% (WACC) | 20.0 % |
|---|--------|
| Target debt ratio (D/(D+E) | 15.0 % |
| Cost of debt | 4.0 % |
| Equity Beta | 1.20 |
| Market risk premium | 4.75% |
| Liquidity premium | 0.60% |
| Risk free interest rate | 2.5 % |
| Cost of equity | 8.8 % |
| Weighted average cost of capital (WACC) | 8.0 % |
| | |

Source: Inderes

Cash flow distribution



Summary

| Income statement | 2020 | 2021 | 2022 | 2023 e | 2024 e | Per share data | 2020 | 2021 | 2022 | 2023 e | 2024 e |
|---------------------------|-------|-------|-------|---------------|---------------|--------------------------|--------|--------|--------|---------------|---------------|
| Revenue | 65.2 | 82.8 | 102.1 | 127.4 | 157.5 | EPS (reported) | 0.22 | 0.25 | 0.27 | 0.22 | 0.29 |
| EBITDA | 23.3 | 27.7 | 32.0 | 36.2 | 41.2 | EPS (adj.) | 0.22 | 0.25 | 0.27 | 0.22 | 0.29 |
| EBIT | 12.9 | 14.8 | 15.3 | 15.5 | 19.6 | OCF / share | 0.54 | 0.66 | 0.68 | 0.76 | 0.87 |
| PTP | 12.0 | 14.0 | 14.6 | 12.7 | 16.4 | FCF / share | 0.04 | -0.26 | -0.31 | -0.19 | -0.09 |
| Net Income | 9.6 | 10.8 | 11.8 | 10.0 | 13.1 | Book value / share | 0.74 | 1.02 | 1.26 | 1.28 | 1.36 |
| Extraordinary items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Dividend / share | 0.15 | 0.17 | 0.18 | 0.19 | 0.20 |
| Balance sheet | 2020 | 2021 | 2022 | 2023 e | 2024e | Growth and profitability | 2020 | 2021 | 2022 | 2023e | 2024 e |
| Balance sheet total | 84.9 | 117.7 | 156.3 | 182.6 | 213.3 | Revenue growth-% | 12% | 27% | 23% | 25% | 24% |
| Equity capital | 32.2 | 44.7 | 56.0 | 58.0 | 62.4 | EBITDA growth-% | 23% | 19% | 16% | 13% | 14% |
| Goodwill | 24.0 | 37.3 | 55.0 | 69.0 | 83.0 | EBIT (adj.) growth-% | 24% | 15% | 3% | 1% | 27% |
| Net debt | 29.0 | 39.2 | 54.1 | 72.9 | 88.2 | EPS (adj.) growth-% | 21% | 11% | 8% | -17% | 30% |
| | | | | | | EBITDA-% | 35.7 % | 33.4 % | 31.4 % | 28.4 % | 26.1 % |
| Cash flow | 2020 | 2021 | 2022 | 2023e | 2024 e | EBIT (adj.)-% | 19.8 % | 17.8 % | 15.0 % | 12.1 % | 12.4 % |
| EBITDA | 23.3 | 27.7 | 32.0 | 36.2 | 41.2 | EBIT-% | 19.8 % | 17.8 % | 15.0 % | 12.1 % | 12.4 % |
| Change in working capital | 2.4 | 3.3 | 0.2 | 1.6 | 2.7 | ROE-% | 34.4 % | 28.1 % | 23.4 % | 17.5 % | 21.8 % |
| Operating cash flow | 23.5 | 28.9 | 30.0 | 34.5 | 40.0 | ROI-% | 19.8 % | 18.0 % | 13.9 % | 11.4 % | 12.3 % |
| CAPEX | -22.2 | -41.9 | -44.5 | -43.1 | -44.1 | Equity ratio | 38.1 % | 38.2 % | 35.9 % | 31.8 % | 29.3 % |
| Free cash flow | 1.8 | -11.3 | -13.8 | -8.5 | -4.1 | Gearing | 90.3 % | 87.7 % | 96.6 % | 125.8 % | 141.3 % |
| | | | | | | | | | | | |
| Valuation multiples | 2020 | 2021 | 2022 | 2023 e | 2024 e | | | | | | |
| EV/S | 10.4 | 6.7 | 4.6 | 3.4 | 2.9 | | | | | | |
| EV/EBITDA (adj.) | 29.2 | 19.9 | 14.8 | 11.9 | 10.9 | | | | | | |

Source: Inderes

EV/EBIT (adj.)

P/E (adj.)

Dividend-%

P/B

52.7

67.9

20.2

1.0 %

37.4

47.5

11.5

1.5 %

31.1

35.4

7.5

1.9 %

27.8

35.8

6.2

2.4 %

23.0

27.6

5.8

2.5 %

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2-4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy The 12-month risk-adjusted expected shareholder return of the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of the share is weak

Sell The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Yhtiö teki 1/5-splitin 25.2.2020, kurssit ja tavoitehinnat oikaistu

| Date | Recommendation | Target | Share price |
|----------|----------------|--------|-------------|
| 24-07-19 | Accumulate | 6.00€ | 5.68€ |
| 30-07-19 | Accumulate | 6.33€ | 6.02€ |
| 22-10-19 | Accumulate | 6.33€ | 5.67€ |
| 08-01-20 | Reduce | 7.33€ | 7.42 € |
| 04-02-20 | Reduce | 7.00€ | 6.97€ |
| 26-02-20 | Accumulate | 6.80€ | 6.40 € |
| 01-04-20 | Reduce | 6.00€ | 5.88€ |
| 28-04-20 | Accumulate | 7.50€ | 7.14 € |
| 15-06-20 | Reduce | 8.20 € | 8.20 € |
| 04-08-20 | Reduce | 9.00€ | 9.32€ |
| 27-10-20 | Reduce | 10.00€ | 10.20€ |
| 19-11-20 | Reduce | 12.00€ | 12.20 € |
| 09-02-21 | Reduce | 12.00€ | 12.50€ |
| 02-03-21 | Accumulate | 12.00€ | 11.15 € |
| 27-04-21 | Reduce | 14.00€ | 14.12 € |
| 03-08-21 | Reduce | 16.00€ | 16.72 € |
| 01-10-21 | Accumulate | 15.00€ | 13.98€ |
| 02-11-21 | Accumulate | 15.50€ | 14.50 € |
| 17-12-21 | Accumulate | 13.50€ | 11.92€ |
| 09-02-22 | Buy | 12.00€ | 9.84€ |
| 13-04-22 | Buy | 12.00€ | 9.99€ |
| 27-04-22 | Buy | 12.00€ | 10.00€ |
| 03-08-22 | Reduce | 12.50€ | 12.30€ |
| 26-10-22 | Reduce | 9.50€ | 9.39€ |
| 01-02-23 | Reduce | 9.00€ | 9.09€ |
| 27-03-23 | Accumulate | 9.00€ | 7.69€ |
| 21-04-23 | Accumulate | 8.80€ | 7.88 € |

inde res.

Inderes connects investors and listed companies. We help over 400 listed companies to better serve their investors. Our community is home to over 70 000 active investors.

Our social objective is to democratize information in the financial markets.

We build solutions for listed companies that enable seamless and effective investor relations. Majority of our revenue comes from services to listed companies, including Commissioned Research, Virtual Events, AGM services, and IR technology and consultation.

Inderes is listed on Nasdaq First North growth market and operates in Finland, Sweden, Norway and Denmark.

Inderes Oyj

Itämerentori 2 FI-00180 Helsinki, Finland +358 10 219 4690

Award-winning research at inderes.fi







Juha Kinnunen 2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen 2014, 2016, 2017, 2019



Sauli Vilén 2012, 2016, 2018, 2019, 2020



Antti Viljakainen 2014, 2015, 2016, 2018, 2019, 2020



Olli Koponen 2020



Joni Grönqvist 2019, 2020



Erkki Vesola 2018, 2020



Petri Gostowski 2020



Atte Riikola 2020

Research belongs to everyone.